Archive · 23 Sep 2026
Glenmark Goa Facility Receives VAI Status After FDA Inspection
Glenmark makes medicines at a factory in Goa.
The US Food and Drug Administration inspected that factory.
The inspection happened from June 22 to June 30.
The FDA gave the factory a report called an Establishment Inspection Report.
It classified the inspection as Voluntary Action Indicated, or VAI.
This means the FDA saw some issues but did not recommend formal regulatory action.
Glenmark is expected to address the issues voluntarily.
The company did not say exactly what the issues or fixes were, and its shares rose slightly after the announcement.
Glenmark Pharmaceuticals received an Establishment Inspection Report from the US Food and Drug Administration for its Goa formulations facility.
The inspection received a Voluntary Action Indicated classification, meaning the FDA observed objectionable conditions but did not recommend regulatory action.
The FDA inspection took place from June 22 to June 30.
Glenmark did not disclose specific observations or corrective actions in its regulatory filing.
Glenmark shares rose 0.28% to Rs 2,470, from a previous close of Rs 2,463.
- Who
- Glenmark Pharmaceuticals and the US Food and Drug Administration.
- What
- The FDA issued an Establishment Inspection Report for Glenmark’s Goa formulations facility with a Voluntary Action Indicated status.
- When
- The inspection took place from June 22 to June 30; Glenmark announced the outcome on September 23, 2026.
- Where
- Glenmark’s formulations manufacturing facility in Goa, India.
- Why
- The FDA issued the report after completing its inspection; the VAI status indicates that voluntary corrective measures are expected.
- Company
- Glenmark Pharmaceuticals Ltd
- Facility
- Formulations manufacturing facility in Goa, India
- Regulator
- US Food and Drug Administration
- Inspection period
- June 22 to June 30
- Inspection outcome
- Establishment Inspection Report with Voluntary Action Indicated status
- Share price reaction
- Shares rose 0.28% to Rs 2,470 from Rs 2,463
- Global presence
- More than 80 countries
